文献速递免疫规划

含SA-2佐剂的融合后流感疫苗通过Th1极化非中和抗体提供异源保护

Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses.
PubMed 文献 · Vaccine · 2023-06-15

本研究在小鼠模型中比较了含合成TLR7激动剂DSP-0546的SA-2佐剂与角鲨烯基MF59类似物分别作为Th1型或Th2型佐剂对融合后流感疫苗的佐剂效应。两种佐剂均 comparable 增强针对异源毒株的交叉反应性IgG滴度,但仅SA-2使IgG亚类向IgG2c偏移并诱导抗体依赖性细胞毒性,最终SA-2佐剂疫苗对致死性异源H3N2和H1N1感染提供保护。

要点

  • SA-2与MF59类似物均增强融合后疫苗针对异源毒株的交叉反应性IgG滴度。
  • 仅SA-2使IgG亚类向IgG2c偏移,与其Th1极化特性相关。
  • SA-2增强的IgG2c应答具抗体依赖性细胞毒性,但无交叉中和活性。

核心结论

  • 与SA-2佐剂联用有利于增强融合后HA疫苗的交叉保护能力,该疫苗诱导非中和性IgG抗体。

研究设计与样本

  • 小鼠模型研究,比较含合成TLR7激动剂DSP-0546的SA-2佐剂与角鲨烯基MF59类似物分别作为Th1型或Th2型佐剂对融合后流感疫苗的佐剂效应。

主要发现

  • 两种佐剂均 comparable 增强融合后疫苗针对异源毒株的交叉反应性IgG滴度。
  • 仅SA-2使IgG亚类向IgG2c偏移,与其Th1极化特性相关。
  • SA-2增强的IgG2c应答对异源病毒株表现出抗体依赖性细胞毒性,无交叉中和活性。
  • SA-2佐剂疫苗接种对致死性异源H3N2和H1N1病毒感染提供保护。

临床怎么用

  • 作者结论认为与SA-2联用有利于增强融合后HA疫苗的交叉保护能力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Development of a universal influenza vaccine that can provide robust and long-lasting protection against heterologous infections is a global public health priority. A variety of vaccine antigens are designed to increase the antigenicity of conserved epitopes to elicit cross-protective antibodies that often lack virus-neutralizing activity. Given the contribution of antibody effector functions to cross-protection, adjuvants need to be added to modulate antibody effector functions as well as to enhance antibody quantity. We previously showed that post-fusion influenza vaccine antigens elicit non-neutralizing but cross-protective antibodies against conserved epitopes. Here, using a murine model, we comparably assessed the adjuvanticity of the newly developed SA-2 adjuvant containing a synthetic TLR7 agonist DSP-0546 and squalene-based MF59 analog as representative Th1- or Th2-type adjuvants, respectively. Both types of adjuvants in the post-fusion vaccine comparably enhanced cross-reactive IgG titers against heterologous strains. However, only SA-2 skewed the IgG subclass into the IgG2c subclass in association to its Th1-polarizing nature. SA-2-enhanced IgG2c responses exhibited antibody-dependent cellular cytotoxicity against heterologous virus strains, without cross-neutralizing activity. Eventually, the SA-2-adjuvanted vaccination provided protection against lethal infection by heterologous H3N2 and H1N1 viruses. Together, we conclude that the combination with a SA-2 is advantageous for enhancing the cross-protective capability of post-fusion HA vaccines that elicit non-neutralizing IgG antibodies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nishiyama A, Adachi Y, Tonouchi K, et al. Post-fusion influenza vaccine adjuvanted with SA-2 confers heterologous protection via Th1-polarized, non-neutralizing antibody responses. Vaccine. 2023. PMID: 37330368. doi:10.1016/j.vaccine.2023.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。